97 related articles for article (PubMed ID: 21627359)
41. p16 and p53 can Serve as Prognostic Markers for Head and Neck Squamous Cell Carcinoma.
Wang Y; Wang F; Wang S; Zhang L; Fu H; Sun L; Wang W; Liu C; Ren W; Gao L; Xing G; Ma X
Int Dent J; 2024 Jun; 74(3):543-552. PubMed ID: 38105167
[TBL] [Abstract][Full Text] [Related]
42. Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
Namazie A; Alavi S; Olopade OI; Pauletti G; Aghamohammadi N; Aghamohammadi M; Gornbein JA; Calcaterra TC; Slamon DJ; Wang MB; Srivatsan ES
Laryngoscope; 2002 Mar; 112(3):472-81. PubMed ID: 12148857
[TBL] [Abstract][Full Text] [Related]
43. Prognostic value of the epidermal growth factor receptor (EGRF) and p53 in advanced head and neck squamous cell carcinoma patients treated with induction chemotherapy.
Hitt R; Ciruelos E; Amador ML; Benito A; Sanchez JJ; Ballestin C; Cortes-Funes H
Eur J Cancer; 2005 Feb; 41(3):453-60. PubMed ID: 15691646
[TBL] [Abstract][Full Text] [Related]
44. Impact of Expression of CD44, a Cancer Stem Cell Marker, on the Treatment Outcomes of Intensity Modulated Radiation Therapy in Patients With Oropharyngeal Squamous Cell Carcinoma.
Motegi A; Fujii S; Zenda S; Arahira S; Tahara M; Hayashi R; Akimoto T
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):461-8. PubMed ID: 26867875
[TBL] [Abstract][Full Text] [Related]
45. Combination of p16(INK4a) /Ki67 immunocytology and HPV polymerase chain reaction for the noninvasive analysis of HPV involvement in head and neck cancer.
Linxweiler M; Bochen F; Wemmert S; Lerner C; Hasenfus A; Bohle RM; Al-Kadah B; Takacs ZF; Smola S; Schick B
Cancer Cytopathol; 2015 Apr; 123(4):219-29. PubMed ID: 25557267
[TBL] [Abstract][Full Text] [Related]
46. High XRCC1 protein expression is associated with poorer survival in patients with head and neck squamous cell carcinoma.
Ang MK; Patel MR; Yin XY; Sundaram S; Fritchie K; Zhao N; Liu Y; Freemerman AJ; Wilkerson MD; Walter V; Weissler MC; Shockley WW; Couch ME; Zanation AM; Hackman T; Chera BS; Harris SL; Miller CR; Thorne LB; Hayward MC; Funkhouser WK; Olshan AF; Shores CG; Makowski L; Hayes DN
Clin Cancer Res; 2011 Oct; 17(20):6542-52. PubMed ID: 21908577
[TBL] [Abstract][Full Text] [Related]
47. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas.
Yuen PW; Man M; Lam KY; Kwong YL
J Clin Pathol; 2002 Jan; 55(1):58-60. PubMed ID: 11825926
[TBL] [Abstract][Full Text] [Related]
48. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation.
van den Broek GB; Wildeman M; Rasch CR; Armstrong N; Schuuring E; Begg AC; Looijenga LH; Scheper R; van der Wal JE; Menkema L; van Diest PJ; Balm AJ; van Velthuysen ML; van den Brekel MW
Int J Cancer; 2009 Jun; 124(11):2643-50. PubMed ID: 19253368
[TBL] [Abstract][Full Text] [Related]
49. Immunometabolic Determinants of Chemoradiotherapy Response and Survival in Head and Neck Squamous Cell Carcinoma.
Krupar R; Hautmann MG; Pathak RR; Varier I; McLaren C; Gaag D; Hellerbrand C; Evert M; Laban S; Idel C; Sandulache V; Perner S; Bosserhoff AK; Sikora AG
Am J Pathol; 2018 Jan; 188(1):72-83. PubMed ID: 29107073
[TBL] [Abstract][Full Text] [Related]
50. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
Brizel DM; Murphy BA; Rosenthal DI; Pandya KJ; Glück S; Brizel HE; Meredith RF; Berger D; Chen MG; Mendenhall W
J Clin Oncol; 2008 May; 26(15):2489-96. PubMed ID: 18487568
[TBL] [Abstract][Full Text] [Related]
51. beta-Tubulin-II expression strongly predicts outcome in patients receiving induction chemotherapy for locally advanced squamous carcinoma of the head and neck: a companion analysis of the TAX 324 trial.
Cullen KJ; Schumaker L; Nikitakis N; Goloubeva O; Tan M; Sarlis NJ; Haddad RI; Posner MR
J Clin Oncol; 2009 Dec; 27(36):6222-8. PubMed ID: 19917838
[TBL] [Abstract][Full Text] [Related]
52. [Comparison of two different chemotherapy regimens for concurrent chemoradiotherapy in stage Ib2 to IVa squamous cell carcinoma of the uterine cervix].
Li XF; Li YH; Gao YN; Li CL; Yue HZ; Xu G; Li DM; Su X
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):763-7. PubMed ID: 24406134
[TBL] [Abstract][Full Text] [Related]
53. Randomized phase III study of 2 cisplatin-based chemoradiation regimens in locally advanced head and neck squamous cell carcinoma: impact of changing disease epidemiology on contemporary trial design.
Rodriguez CP; Adelstein DJ; Rybicki LA; Savvides P; Saxton JP; Koyfman SA; Greskovich JF; Yao M; Scharpf J; Lavertu P; Wood BG; Burkey BB; Lorenz RR; Rezaee RP; Zender CA; Ives DI
Head Neck; 2015 Nov; 37(11):1583-9. PubMed ID: 24909549
[TBL] [Abstract][Full Text] [Related]
54. Induction Chemotherapy and Sequential Concomitant Chemo-radiation in Locally Advanced Head and Neck Cancers: How Induction-phase Intensity and Treatment Breaks May Impact on Clinical Outcomes.
Franco P; Potenza I; Schena M; Riva G; Pecorari G; Garzino Demo P; Fasolis M; Moretto F; Garzaro M; Di Muzio J; Melano M; Airoldi M; Ragona R; Rampino M; Ricardi U
Anticancer Res; 2015 Nov; 35(11):6247-54. PubMed ID: 26504058
[TBL] [Abstract][Full Text] [Related]
55. Expression of p53, p21 and p16 does not correlate with response to preoperative chemoradiation in gastric carcinoma.
Sirak I; Petera J; Hatlova J; Vosmik M; Melichar B; Dvorak J; Tycova V; Zoul Z; Lesko M
Hepatogastroenterology; 2009; 56(93):1213-8. PubMed ID: 19760973
[TBL] [Abstract][Full Text] [Related]
56. Rate of pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck.
Haddad R; Tishler R; Wirth L; Norris CM; Goguen L; Sullivan C; O'Donnell L; Li Y; Posner M
Arch Otolaryngol Head Neck Surg; 2006 Jun; 132(6):678-81. PubMed ID: 16785415
[TBL] [Abstract][Full Text] [Related]
57. Effect of comorbidity on quality of life and treatment selection in patients with squamous cell carcinoma of the head and neck.
Gourin CG; McAfee WJ; Neyman KM; Howington JW; Podolsky RH; Terris DJ
Laryngoscope; 2005 Aug; 115(8):1371-5. PubMed ID: 16094107
[TBL] [Abstract][Full Text] [Related]
58. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
59. Roles of Ki-67 and p16 as biomarkers for unknown primary head and neck squamous cell carcinoma.
Maebayashi T; Ishibashi N; Aizawa T; Sakaguchi M; Saito T; Kawamori J; Tanaka Y; Hirotani Y; Homma T
Eur Arch Otorhinolaryngol; 2019 Apr; 276(4):1221-1229. PubMed ID: 30756227
[TBL] [Abstract][Full Text] [Related]
60. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
